These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36963127)

  • 1. Efficacy and tolerance of methotrexate in a real-life monocentric cohort of patients with giant cell arteritis.
    Lavergne A; Dumont A; Deshayes S; Boutemy J; Maigné G; Silva NM; Nguyen A; Gallou S; Philip R; Aouba A; de Boysson H
    Semin Arthritis Rheum; 2023 Jun; 60():152192. PubMed ID: 36963127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Meteoritics Trial: efficacy of methotrexate after remission-induction with tocilizumab and glucocorticoids in giant cell arteritis-study protocol for a randomized, double-blind, placebo-controlled, parallel-group phase II study.
    Kreis L; Dejaco C; Schmidt WA; Németh R; Venhoff N; Schäfer VS
    Trials; 2024 Jan; 25(1):56. PubMed ID: 38225579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature.
    Kötter I; Henes JC; Wagner AD; Loock J; Gross WL
    Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S114-29. PubMed ID: 22640655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Methotrexate in Real-world Management of Giant Cell Arteritis: A Case-control Study.
    Koster MJ; Yeruva K; Crowson CS; Muratore F; Labarca C; Warrington KJ
    J Rheumatol; 2019 May; 46(5):501-508. PubMed ID: 30647171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Faster steroid-free remission with tocilizumab compared to methotrexate in giant cell arteritis: a real-life experience in two reference centres.
    Quartuccio L; Treppo E; De Martino M; Pillon M; Perniola S; Bruno D; Isola M; Gremese E
    Intern Emerg Med; 2024 Aug; ():. PubMed ID: 39093541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis.
    Mahr AD; Jover JA; Spiera RF; Hernández-García C; Fernández-Gutiérrez B; Lavalley MP; Merkel PA
    Arthritis Rheum; 2007 Aug; 56(8):2789-97. PubMed ID: 17665429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review.
    de Boysson H; Boutemy J; Creveuil C; Ollivier Y; Letellier P; Pagnoux C; Bienvenu B
    Semin Arthritis Rheum; 2013 Aug; 43(1):105-12. PubMed ID: 23453684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with methotrexate and risk of relapses in patients with giant cell arteritis in clinical practice.
    Leon L; Rodriguez-Rodriguez L; Morado I; Rosales Z; Vadillo C; Freites D; Macarron P; Fernandez-Gutierrez B; Blanco M; Jover JA; Abasolo L
    Clin Exp Rheumatol; 2018; 36 Suppl 111(2):121-128. PubMed ID: 29303708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnostics and treatment of giant cell arteritis].
    Kraemer M; Becker J; Bley TA; Steinbrecher A; Minnerup J; Hellmich B
    Nervenarzt; 2022 Aug; 93(8):819-827. PubMed ID: 34734295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low relapse rate in patients with giant cell arteritis in a multi-centre retrospective Turkish Registry.
    Alibaz-Öner F; Kelesoglu B; Balci MA; Yardimci GK; Armağan B; Kiliç L; Karakaş Ö; Erden A; Yasar Bilge S; Kardaş RC; Küçük H; Zengin O; Tasci M; Kocaer SB; Yavuz S; Dogru A; Şahin M; Bayindir O; Sevik G; Ertürk Z; Alpay-Kanitez N; Gogebakan H; Tezcan ME; Oksuz MF; Cefle A; Kucuksahin O; Yazici A; Kasapoglu E; Bes C; Unal AU; Dalkiliç E; Yildirim Çetin G; Aksu K; Keser G; Onen F; Çobankara V; Kisacik B; Onat AM; Öztürk MA; Kaşifoğlu T; Omma A; Karadag O; Ates A; Direskeneli H
    Clin Exp Rheumatol; 2024 Apr; 42(4):816-821. PubMed ID: 37976117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucocorticoid dosing and relapses in giant cell arteritis-a single centre cohort study.
    Felten L; Leuchten N; Aringer M
    Rheumatology (Oxford); 2022 May; 61(5):1997-2005. PubMed ID: 34487149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and Future.
    Hellmich B; Águeda AF; Monti S; Luqmani R
    Curr Rheumatol Rep; 2020 Oct; 22(12):84. PubMed ID: 33044642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study.
    Schönau V; Roth J; Tascilar K; Corte G; Manger B; Rech J; Schmidt D; Cavallaro A; Uder M; Crescentini F; Boiardi L; Casali M; Spaggiari L; Galli E; Kuwert T; Versari A; Salvarani C; Schett G; Muratore F
    Rheumatology (Oxford); 2021 Aug; 60(8):3851-3861. PubMed ID: 33831144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of leflunomide in the management of large vessel vasculitis: A systematic review and metaanalysis of cohort studies.
    Narváez J; Estrada P; LLop D; Vidal-Montal P; Brugarolas E; Maymó-Paituvi P; Palacios-Olid J; Nolla JM
    Semin Arthritis Rheum; 2023 Apr; 59():152166. PubMed ID: 36645992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trial.
    Marsman DE; Bolhuis TE; den Broeder N; den Broeder AA; van der Maas A
    Trials; 2022 Apr; 23(1):318. PubMed ID: 35428320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis.
    Hoffman GS; Cid MC; Hellmann DB; Guillevin L; Stone JH; Schousboe J; Cohen P; Calabrese LH; Dickler H; Merkel PA; Fortin P; Flynn JA; Locker GA; Easley KA; Schned E; Hunder GG; Sneller MC; Tuggle C; Swanson H; Hernández-Rodríguez J; Lopez-Soto A; Bork D; Hoffman DB; Kalunian K; Klashman D; Wilke WS; Scheetz RJ; Mandell BF; Fessler BJ; Kosmorsky G; Prayson R; Luqmani RA; Nuki G; McRorie E; Sherrer Y; Baca S; Walsh B; Ferland D; Soubrier M; Choi HK; Gross W; Segal AM; Ludivico C; Puechal X;
    Arthritis Rheum; 2002 May; 46(5):1309-18. PubMed ID: 12115238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors Associated with Relapse and Dependence on Glucocorticoids in Giant Cell Arteritis.
    Dumont A; Parienti JJ; Delmas C; Boutemy J; Maigné G; Martin Silva N; Sultan A; Planchard G; Aouba A; de Boysson H
    J Rheumatol; 2020 Jan; 47(1):108-116. PubMed ID: 30877210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?
    van der Veen MJ; Dinant HJ; van Booma-Frankfort C; van Albada-Kuipers GA; Bijlsma JW
    Ann Rheum Dis; 1996 Apr; 55(4):218-23. PubMed ID: 8733437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of giant cell arteritis].
    Samson M; Greigert H; Bonnotte B
    Rev Prat; 2023 Apr; 73(4):395-399. PubMed ID: 37289152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Glucocorticoids in the treatment of giant cell arteritis : How much, how long and how to spare?].
    Hellmich B
    Z Rheumatol; 2021 May; 80(4):322-331. PubMed ID: 33710440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.